DRG Market Assessment reports

Over the next ten years, more than 15 million men worldwide Despite the tremendous potential of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, limited market access will…

By definition, rare diseases affect relatively few individual patients, but as a group they encompass up to 8,000 recognized rare diseases affecting approximately 10% of the U.S. population. The…

Outpatient parenteral antimicrobial therapy (OPAT) allows patients with clinically stable infections (e.g., skin and soft tissue infections, bone and joint infections, osteomyelitis, intra-…

Glaucoma refers to a group of chronic, progressive eye diseases caused primarily by elevated intraocular pressure (IOP), which left untreated can lead to damage of the optic nerve and eventual…

The availability of novel disease-modifying therapies (DMTs)—oral DMTs, Plegridy, and Lemtrada—has complicated clinical decision making and treatment choice in the management of multiple…

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease (MND), is a degenerative disorder of the nervous system characterized by progressive muscle…

For the estimated 9.5 million people in the United States who are living with a history of diagnosed psoriasis, there are multiple prescription therapies that are available for treating the mild to…

For the estimated 36 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its…

The symptomology of Parkinson’s disease (PD) is heterogeneous; individual patients experience different combinations of primary motor symptoms, complications of therapy, and/or key nonmotor…

Osteoporosis is a common bone disease estimated to have affected 24.5 million U.S. patients in 2014, although owing to the asymptomatic nature of osteoporosis, the disease remains underdiagnosed. U…

Last Updated 2 October 2015 A new era in the market for multiple sclerosis (MS) disease-modifying therapies (DMTs) has dawned: Novartis/Mitsubishi Tanabe Pharma’s fingolimod (Gilenya/Imusera)…

Over the next ten years, more than 15 million men worldwide will be diagnosed with prostate cancer, resulting in nearly 3 million first-line drug-treatment opportunities in the metastatic castrate-…